Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
1.079 Leser
Artikel bewerten:
(2)

MZHCI, LLC: SANUWAVE Health Provides Business Update

Finanznachrichten News

SUWANEE, GA / ACCESSWIRE / July 2, 2021 / SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation wound care products has announced that as of July 2, 2021 the company's shares will no longer be traded on the OTCQB due to failure to timely file quarterly financials with the Securities & Exchange Commission. The shares will commence trading on the pink sheets under the symbol SNWV.

Kevin Richardson, Chairman and Chief Executive Officer of SANUWAVE said, "Our inability to have timely financial results and documents was due, in part, to accounting systems implementation issues. The management team remains focused on resolving this issue and completing our financial filings. In fact, we have now filed our third quarter 2020 form 10Q and anticipate our 2020 annual report on form 10K will be filed in the next few weeks. We do not anticipate this will be an ongoing issue in the future. As soon as we are able to be current with our filings we will then have our shares re-listed on the OTCQB.

"Our business operations remain strong and growth prospects, both domestic and international, are promising. We recently signed a distribution agreement with one of the largest medical products distributors in Latin America, recently published clinical studies have shown our products have strong efficacy and we remained focused on growing the business and establishing SANUWAVE as one of the premier wound healing product companies in the world. We have seen an uptick in dermaPACE Systems placements as a direct result of the sales focus and positive reimbursement environment for the product. UltraMIST systems sales are having a record year to date, with the largest numbers of trials underway in company history.

"Our rebranding and relaunching of the ENERGY FIRST platform has been well received and is building momentum. Given this platform we have been able to add eight industry veterans to our sales team who will begin to add to the building sales growth and increasing sales pipeline. We fully expect 2021 to be a record year for Sanuwave. We appreciate our investors' continued patience and understanding."

About SANUWAVE Health

SANUWAVE Health (OTCQB: SNWV) is focused on the research, development, and commercialization of its patented, Energy First non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVE's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body's normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac/endovascular conditions. For more information, please visit. www.SANUWAVE.com.

Investor Relations Contact
Brian M. Prenoveau, CFA
Managing Director
MZ Group - MZ North America
(561) 489-5315
SNWV@mzgroup.us
www.mzgroup.us

SOURCE: MZHCI, LLC



View source version on accesswire.com:
https://www.accesswire.com/654105/SANUWAVE-Health-Provides-Business-Update

© 2021 ACCESSWIRE
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.